XU Yinxue,ZHANG Lei,QIAO Xiwen,et al.Efficacy and safety of antibody-drug conjugates in the treatment of breast cancer:a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(20):2540-2544.
XU Yinxue,ZHANG Lei,QIAO Xiwen,et al.Efficacy and safety of antibody-drug conjugates in the treatment of breast cancer:a meta-analysis[J].ZHONGGUO YAOFANG,2023,34(20):2540-2544. DOI: 10.6039/j.issn.1001-0408.2023.20.17.
Efficacy and safety of antibody-drug conjugates in the treatment of breast cancer:a meta-analysis
To evaluate the efficacy and safety of antibody-drug conjugates (ADC) in the treatment of breast cancer, so as to provide an evidence-based reference for clinical medication.
METHODS
2
Retrieved from CNKI, Wanfang database, VIP, PubMed, the Cochrane Library, Embase, and Web of Science, randomized controlled trials (RCTs) about trastuzumab emtansine, trastuzumab deruxtecan and sacituzumab govitecan (trial group) versus chemotherapy or other anti-tumor drugs (control group), were collected during the inception to April 2023. After screening the literature, extracting data, and evaluating the quality of the literature, a meta-analysis was conducted by using RevMan 5.4.1 software.
RESULTS
2
A total of 8 RCTs were included, with a total of 5 577 patients. The results of the meta-analysis showed that the progression-free survival (PFS) [HR=0.76, 95%CI (0.69, 0.83),
=0.02] of the trial group were significantly higher than control group. There was no statistically significant difference in objective response rate (ORR) between the two groups [OR=2.34, 95%CI (0.59, 9.33),
P
=0.23]. The results of subgroup analysis showed that the PFS of HER2-positive patients and HER2-negative patients, and the OS of HER2-positive patients in the trial group were significantly higher than control group (
P
<0.05). The incidence of anemia and increase of aspartic acid transaminase (AST) in the trial group was significantly higher than control group (
P
<0.05). The results of sensitivity analysis showed that the results obtained with PFS, OS, and ORR as indicators were relatively robust, while the results obtained with CBR as indicators lacked robustness.
CONCLUSIONS
2
ADC drugs have significant effects on breast cancer, but will increase the risk of anemia and elevated AST.
SUNG H,FERLAY J,SIEGEL R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
TSUCHIKAMA K,AN Z Q. Antibody-drug conjugates:recent advances in conjugation and linker chemistries[J]. Protein Cell,2018,9(1):33-46.
GRADISHAR W J,MORAN M S,ABRAHAM J,et al. Breast cancer,version 3.2022,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2022,20(6):691-722.
Guidelines Working Committee of the Chinese Clinical Oncology Society. Guidelines of Chinese Society of Clinical Oncology(CSCO):breast cancer 2023[M]. Beijing:People’s Health Publishing House,2023:1-210.
CORTÉS J,KIM S B,CHUNG W P,et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer[J]. N Engl J Med,2022,386(12):1143-1154.
BARDIA A,TOLANEY S M,LOIRAT D,et al. LBA17 ASCENT:a randomized phase Ⅲ study of sacituzumab govitecan(SG) vs treatment of physician’s choice(TPC) in patients(pts)with previously treated metastatic triple-negative breast cancer(mTNBC)[J]. Ann Oncol,2020,31:S1149-S1150.
BARDIA A,MAYER I A,VAHDAT L T,et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med,2019,380(8):741-751.
The Cochrane Collbration. Cochrane handbook for systematic reviews of interventions,version5.1.0[EB/OL].[2023-03-15]. http://handbook-5-1.cochrane.org/http://handbook-5-1.cochrane.org/.
RUGO H S,BARDIA A,MARMÉ F,et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol,2022,40(29):3365-3376.
BARDIA A,HURVITZ S A,TOLANEY S M,et al. Sacituzumab govitecan in metastatic triple-negative breast cancer[J]. N Engl J Med,2021,384(16):1529-1541.
HURVITZ S A,DIRIX L,KOCSIS J,et al. Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J]. J Clin Oncol,2013,31(9):1157-1163.
MODI S N,JACOT W,YAMASHITA T,et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med,2022,387(1):9-20.
DIÉRAS V,MILES D,VERMA S,et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J]. Lancet Oncol,2017,18(6):732-742.
VON MINCKWITZ G,HUANG C S,MANO M S,et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J]. N Engl J Med,2019,380(7):617-628.
KROP I E,KIM S B,MARTIN A G,et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer(TH3RESA):final overall survival results from a randomised open-label phase 3 trial[J]. Lancet Oncol,2017,18(6):743-754.
PEREZ E A,BARRIOS C,EIERMANN W,et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer:final results from MARIANNE[J]. Cancer,2019,125(22):3974-3984.
XU Z Y,GUO D D,JIANG Z L,et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer:trastuzumab deruxtecan(DS-8201a)and (vic-)trastuzumab duocarmazine(SYD985)[J]. Eur J Med Chem,2019,183:111682.
SHARKEY R M,MCBRIDE W J,CARDILLO T M,et al. Enhanced delivery of SN-38 to human tumor xenografts with an anti-trop-2-SN-38 antibody conjugate(sacituzumab govitecan)[J]. Clin Cancer Res,2015,21(22):5131-5138.
VERMA S,MILES D,GIANNI L,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med,2012,367(19):1783-1791.
MODI,PARK H,MURTHY R K,et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer:results from a phase Ⅰ b study[J]. J Clin Oncol,2020,38(17):1887-1896.
BARDIA A,MAYER I A,DIAMOND J R,et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan(IMMU-132)in heavily pretreated patients with metastatic triple-negative breast cancer[J]. J Clin Oncol,2017,35(19):2141-2148.
KUNST N,WANG S Y,HOOD A,et al. Cost-effective-ness of neoadjuvant-adjuvant treatment strategies for women with ERBB2(HER2)-positive breast cancer[J]. JAMA Netw Open,2020,3(11):e2027074.
MASTERS J C,NICKENS D J,XUAN D W,et al. Clinical toxicity of antibody drug conjugates:a meta-analysis of payloads[J]. Invest New Drugs,2018,36(1):121-135.
ZHANG L Y,SHEN D Y,YU L L,et al. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2022,177:103758.
YAN H H,ENDO Y,SHEN Y,et al. Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity[J]. Mol Cancer Ther,2016,15(3):480-490.
Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis
Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation
Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer: a meta-analysis
Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia
Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia
Related Author
WANG Mingjie
XU Fengjin
ZHANG Yan
XUE Yan
WU Jiaqian
SU Dan
SHAO Tenghao
YU Zhanbiao
Related Institution
Dept. of General Medicine, Hengshui Municipal People’s Hospital
College of Clinical Medicine, Hebei Medical University
Dept. of Rheumatology and Immunology, Hengshui Municipal People’s Hospital
Dept. of Intensive Care Medicine, the Fourth Hospital of Hebei Medical University
Dept. of Intensive Care Medicine, the Affiliated Hospital of Hebei University